by Riley Nolan | Jun 14, 2021 | Featured, Thinking Out Loud -Blog
The Curious Case of HCP-driven Immunogenicity The FDA briefly “paused” the Johnson & Johnson adenovirus-based COVID-19 vaccine in April, and the AstraZeneca vaccine (also adenovirus-based) was in the news as early as March. Both of these pauses were to...
by Riley Nolan | Jun 10, 2021 | Featured, Thinking Out Loud -Blog
EpiVax has been busy helping our clients, and the research flywheel is spinning faster than ever. We needed more talented folks to pitch in! So far we’ve brought on six wonderful team members in 2021, with more to come soon! Learn more about our new folks below,...
by Riley Nolan | May 21, 2021 | Events, Featured, Webinars
EpiVax CEO/CSO Annie De Groot and Director of Analysis Frances Terry co-presented “Engineering Better Biologics: Does Nature Know Best?” at the 2021 AAPS NBC conference May 19th 2021. Outline: Background on T cells / Immunogenicity EpiMatrix, JanusMatrix ...
by Riley Nolan | May 18, 2021 | Featured, Thinking Out Loud -Blog
The news from Mali Here in Bamako, life is really not that much different from so many other countries. On the street, the average citizen is still hawking gasoline in glass bottles for 500 CFA, selling sunglasses at traffic stops, or herding goats across the road,...
by Riley Nolan | May 17, 2021 | Featured, News
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...